Literature DB >> 24464917

Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells.

Audrey Joannes1, Simon Grelet, Laurent Duca, Christine Gilles, Claire Kileztky, Véronique Dalstein, Philippe Birembaut, Myriam Polette, Béatrice Nawrocki-Raby.   

Abstract

UNLABELLED: In many cancers, including lung carcinomas, Fragile histidine triad (Fhit) is frequently decreased or lost. Fhit status has recently been shown to be associated with elevated in vitro and in vivo invasiveness in lung cancer. Tumor cell invasion is facilitated by epithelial-mesenchymal transition (EMT), a process by which tumor cells lose their epithelial features to acquire a mesenchymal cell-like phenotype. In this study, the mechanism underlying Fhit-regulated EMT was deciphered. Using Slug knockdown, pharmacologic inhibitors PD98059, PP1, and gefitinib as well as an anti-EGFR antibody, it was demonstrated that Fhit silencing in bronchial cells induced overexpression of two primary EMT-associated targets, MMP-9 and vimentin, to regulate cell invasion dependent on an EGFR/Src/ERK/Slug signaling pathway. Moreover, ectopic expression of Fhit in Fhit-deficient lung cancer cells downregulated this pathway. Finally, an inverse correlation was observed between Fhit and phospho-EGFR levels in a cohort of human squamous cell lung carcinoma specimens. These results demonstrate a Fhit-dependent mechanism in the control of EMT-regulated EGFR signaling. IMPLICATIONS: This study adds new insight into the regulatory mechanism of EMT, a process known to increase resistance to conventional and targeted therapies in lung cancer. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464917     DOI: 10.1158/1541-7786.MCR-13-0386-T

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  23 in total

1.  Identification of Fhit as a post-transcriptional effector of Thymidine Kinase 1 expression.

Authors:  Daniel L Kiss; Catherine E Waters; Iman M Ouda; Joshua C Saldivar; Jenna R Karras; Zaynab A Amin; Seham Mahrous; Teresa Druck; Ralf A Bundschuh; Daniel R Schoenberg; Kay Huebner
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-14       Impact factor: 4.490

2.  A knockdown with smoke model reveals FHIT as a repressor of Heme oxygenase 1.

Authors:  Jennifer A Boylston; Charles Brenner
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

3.  Targeting of sonic hedgehog-Gli signaling: A potential therapeutic target for patients with breast cancer.

Authors:  Lingqin Song; Weifeng Wang; Di Liu; Yang Zhao; Jianjun He; Xijing Wang; Zhijun Dai; Huimin Zhang; Xiao Li
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

Review 4.  The FHIT gene product: tumor suppressor and genome "caretaker".

Authors:  Catherine E Waters; Joshua C Saldivar; Seyed Ali Hosseini; Kay Huebner
Journal:  Cell Mol Life Sci       Date:  2014-10-05       Impact factor: 9.261

5.  Tanshinones induce tumor cell apoptosis via directly targeting FHIT.

Authors:  Xianglian Zhou; Yuting Pan; Yue Wang; Bojun Wang; Yu Yan; Yi Qu; Xisong Ke
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

6.  FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs.

Authors:  Sung-Suk Suh; Ji Young Yoo; Ri Cui; Balveen Kaur; Kay Huebner; Taek-Kyun Lee; Rami I Aqeilan; Carlo M Croce
Journal:  PLoS Genet       Date:  2014-10-23       Impact factor: 5.917

7.  FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.

Authors:  Svenja Dannewitz Prosseda; Xuefei Tian; Kazuya Kuramoto; Mario Boehm; Deepti Sudheendra; Kazuya Miyagawa; Fan Zhang; David Solow-Cordero; Joshua C Saldivar; Eric D Austin; James E Loyd; Lisa Wheeler; Adam Andruska; Michele Donato; Lingli Wang; Kay Huebner; Ross J Metzger; Purvesh Khatri; Edda Spiekerkoetter
Journal:  Am J Respir Crit Care Med       Date:  2019-01-01       Impact factor: 30.528

8.  Association of activated Gαq to the tumor suppressor Fhit is enhanced by phospholipase Cβ.

Authors:  Hao Zuo; Yung H Wong
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

9.  Transketolase Serves a Poor Prognosticator in Esophageal Cancer by Promoting Cell Invasion via Epithelial-Mesenchymal Transition.

Authors:  Yin-Kai Chao; Ta-Lun Peng; Wen-Yu Chuang; Chi-Ju Yeh; Yan-Liang Li; Ya-Ching Lu; Ann-Joy Cheng
Journal:  J Cancer       Date:  2016-08-12       Impact factor: 4.207

10.  Fhit loss-associated initiation and progression of neoplasia in vitro.

Authors:  Jenna R Karras; Morgan S Schrock; Bahadir Batar; Jie Zhang; Krista La Perle; Teresa Druck; Kay Huebner
Journal:  Cancer Sci       Date:  2016-10-03       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.